Developing new gene therapies for autosomal dominant polycystic kidney disease (ADPKD) is still a challenge to date. A group of researchers from the Johns Hopkins Medicine in Baltimore has presented ...
Nine out of 10 people with chronic kidney disease only find out when it progresses to later stages. Here’s what we know about its risk factors—and why there's new reason to hope for more effective ...
Pove was generally safe and well tolerated with adverse events (AEs) that were mostly mild or moderate in severity. There were no serious adverse events related to povetacicept. The safety data is ...
In the phase 2 MIRO-CKD trial, investigators tested a novel MRA in combination with an SGLT2 inhibitor and included patients with higher serum potassium levels than 4.8 mmol/L at baseline and patients ...
The alliance between AbbVie and Calico dates back to 2014, just a year after it was launched by Alphabet's Google unit, when ...
In this free webinar, gain insight into the main challenges in patient recruitment for autosomal dominant polycystic kidney disease (ADPKD) clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback